Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...
The Lancet16d
Retraction and republication—Feeding dystonia, chorea, psychosis, and self-mutilation in an African patient with neuroacanthocytosis syndrome
The Lancet has discovered that our editorial policies prior to the publication of the Clinical Picture Feeding dystonia, chorea, psychosis, and self-mutilation in an African patient with ...
The Lancet16d
Feeding dystonia, chorea, psychosis, and self-mutilation in an African patient with neuroacanthocytosis syndrome
A 34-year-old woman with a 2-year history of progressively worsening difficulties in walking, eating and swallowing, presented to our department. The patient's sister reported observing unusual ...